Roche Holding AG risk profile
32 Normal where most of the sector sits
Measured 1 September 2026 from RO's filed statements. Recomputed nightly.
32 (Normal), driven by Competitive position at 44, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 24 | Normal | Stable | One-year price volatility — 25.7% |
| Operating pressure | 21 | Normal | Easing | Operating-margin drift — +2.6 percentage points |
| Cash conversion | 24 | Normal | Worsening | Capital spending against operating cash — 0.31x |
| Leverage and coverage | 22 | Normal | Easing | Current ratio — 1.38x |
| Competitive position | 44 | Elevated | Stable | Revenue-growth gap against peers — -33.7 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 17Johnson & Johnson 37Abbvie Inc 46Merck & Co Inc 26Novartis AG 25Astrazeneca plc 30AMGEN Inc 33Thermo Fisher Scientific Inc 45Novo Nordisk A/S 23Abbott Laboratories 43Gilead Sciences Inc 31Pfizer Inc 44
Financials, valuation and price history for Roche Holding AG